I noticed some in this recent cohort had 177lu and 255ac. I can see how this would've played a part in how well patients would've responded to cu67. If 255ac isn't approved, why would the FDA consider having 255ac as a prereq for P3?
Despite all this, 44% had PSA over 50% on a single dose(pluvicto was ~46%).
Ann: Theranostic prostate cancer trial advances to multi-dose, page-21
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.09 |
Change
0.230(4.73%) |
Mkt cap ! $1.586B | |||
| Open | High | Low | Value | Volume |
| $4.95 | $5.11 | $4.87 | $4.562M | 911.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4449 | $5.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.09 | 567 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |